


# Advancing monoclonal antibodies to restore the ability to control bacterial infection

Antimicrobial resistance is a major threat to public health globally

But susceptibility to bacterial infection is determined by the body's immune response




Immunetep is developing antibody therapies targeting a protein secreted by bacteria such as *E. coli* and *K. pneumoniae*



This protein is called bacterial GAPDH (bGAPDH) and limits the body's ability to fight off infection

The antibodies being developed bind to the secreted bGAPDH and block its function



The immune system can then better fight off the infection by eliminating the bacteria

The Immunetep team has identified a promising series of monoclonal antibodies that target bGAPDH



16 of these antibodies have shown tight binding to bGAPDH and are being tested further



Funding and collaborative support from PACE will allow four of the best antibodies to be selected for efficacy and safety studies

At least one antibody will be chosen for development through to clinical studies



Success will result in an antibody-based treatment

- Protects against infection from both *E. coli* and *K. pneumoniae*
- Single dose
- No associated toxicity
- No antimicrobial resistance

